

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

SCHERING-PLOUGH LEGISLATIVE RESOURCES

2. Address:

1130 CONNECTICUT AVENUE, NW, #500, WASHINGTON, DC 20036

3. Principal place of business (if different from line 2):

4. Contact Name: MARRA BUSSEY

Telephone: 2024637372

E-mail (optional): marra.bussey@spcorp.com

Senate ID #: 34502-12

House ID #:

7. Client Name: ☒ Self

TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): ☐ **OR** Year End (July 1 - December 31): ☒

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Expenses (nearest \$20,000): 1,180,000.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

☒ **Method A.** Reporting amounts using LDA definitions only

☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: ANI (one per page)

16. Specific lobbying issues:

Legislative proposals regarding national animal ID program and country of origin labeling: H.R.2419, Farm, Nutrition, and Bioenergy Act of 2007; H.R.3161, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008; S.1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008. H.R.2419, Farm, Nutrition, and Bioenergy Act of 2007; H.R.3161, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008; S.1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008.

17. House(s) of Congress and Federal agencies contacted:
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ATKINS, LARRY
Covered Official Position (if applicable): N/A
Name: EHRLICH, PAUL
Covered Official Position (if applicable): N/A
Name: LIVELY, ROBERT W.
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

Legislative proposals affecting US patent system: H.R.1908, Patent Reform Act of 2007; S.1145, Patent Reform Act of 2007.
Legislative proposals regarding follow-on biologics: H.R.1038, Access to Life-Saving Medicine Act; S.623, Access to Life-Saving Medicine Act; S.1082, Food and Drug Administration Revitalization Act; S.1505, Affordable Biologics for Consumers Act. Legislative proposals regarding brand-generic drug firm agreements: S.316, Preserve Access to Affordable Generics Act. H.R.1038, Access to Life-Saving Medicine Act; H.R.1908, Patent Reform Act of 2007; S.316, Preserve Access to Affordable Generics Act; S.623, Access to Life-Saving Medicine Act; S.1082, Food and Drug Administration Revitalization Act; S.1145, Patent Reform Act of 2007; S.1505, Affordable Biologics for Consumers Act.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ATKINS, LARRY

Covered Official Position (if applicable): N/A

Name: EHRLICH, PAUL

Covered Official Position (if applicable): N/A

Name: LIVELY, ROBERT W.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

S.242, Pharmaceutical Market Access and Drug Safety Act of 2007; S.468, Food and Drug Administration Safety Act of 2007; S.484, Enhancing Drug Safety and Innovation Act of 2007; S.830, Pediatric Medical Device Safety and Improvement Act of 2007; S.993, Pediatric Research Improvement Act; S.1082, Food and Drug Administration Revitalization Act; S.1547, National Defense Authorization Act for Fiscal Year 2008; S.1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008; S.2331, Non-prescription Drug Modernization Act of 2007; S.ConRes.21, Concurrent resolution setting forth the congressional budget for the United States. Legislative proposals to extend federal contract prices to the retail section in the TRICARE program: H.R.1585, National Defense Authorization Act for Fiscal Year 2008; S.1547, National Defense Authorization Act for Fiscal Year 2008. Legislative proposals permitting importation of prescription drugs from overseas: H.R.2638, Department of Homeland Security Appropriations Act, 2008; H.R.3161, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008; H.R.3162, Children's Health and Medicare Protection Act of 2007; S.242, Pharmaceutical Market Access and Drug Safety Act of 2007; S.1082, Food and Drug Administration Revitalization Act; S.1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008; S.ConRes.21, Concurrent resolution setting forth the congressional budget for the United States. Legislative proposals regarding drug safety, clinical trial registries, DTC advertising, and reauthorization of the Prescription Drug User Fee Act, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act: H.R.2900, Food and Drug Administration Amendments Act of 2007; S.468, Food and Drug Administration Safety Act of 2007; S.484, Enhancing Drug Safety and Innovation Act of 2007; S.830, Pediatric Medical Device Safety and Improvement Act of 2007; S.993, Pediatric Research Improvement Act; S.1082, Food and Drug Administration Revitalization Act; S.1547, National Defense Authorization Act for Fiscal Year 2008. Legislative proposals regarding FDA funding: H.R.3161, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008; S.1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008. Legislative proposals to ensure access to meth-safe alternative medicines: H.R.3161, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008; S.1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008. Legislative proposals to reform the OTC monograph system: H.R.4083, Non-prescription Drug Modernization Act of 2007; S.2331, Non-prescription Drug Modernization Act of 2007. Response to congressional investigation regarding ENHANCE study: H.R.1585, National Defense Authorization Act for Fiscal Year 2008; H.R.2638, Department of Homeland Security Appropriations Act, 2008; H.R.2900, Food and Drug Administration Amendments Act of 2007; H.R.3161, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008; H.R.3162, Children's Health and Medicare Protection Act of 2007; H.R.4083, Non-prescription Drug Modernization Act of 2007;

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ATKINS, LARRY

Covered Official Position (if applicable): N/A

Name: EHRLICH, PAUL

Covered Official Position (if applicable): N/A

Name: LIVELY, ROBERT W.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: LBR (one per page)

16. Specific lobbying issues:

Legislative proposals regarding shareholder participation in corporate executive compensation decisions: H.R.2, Fair Minimum Wage Act of 2007; H.R.976, Children's Health Insurance Program Reauthorization Act of 2007; H.R.1257, Shareholder Vote on Executive Compensation Act. H.R.2, Fair Minimum Wage Act of 2007; H.R.976, Children's Health Insurance Program Reauthorization Act of 2007; H.R.1257, Shareholder Vote on Executive Compensation Act.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ATKINS, LARRY

Covered Official Position (if applicable): N/A

Name: EHRLICH, PAUL

Covered Official Position (if applicable): N/A

Name: LIVELY, ROBERT W.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

S.965,U.S. Troop Readiness, Veterans' Care, Katrina Recovery, and Iraq Accountability Appropriations Act, 2007; SConRes.21, Concurrent resolution setting forth the congressional budget for the United States. Legislative proposals to repeal Medicare "non-interference" provisions: H.R.4, Medicare Prescription Drug Price Negotiation Act of 2007; S.3, Medicare Prescription Drug Price Negotiation Act of 2007; S.250, Medicare Enhancements for Needed Drugs Act of 2007; SConRes.21, Concurrent resolution setting forth the congressional budget for the United States. Legislative proposals effecting Medicaid "average manufactureres' price" AMP: H.R.3162, Children's Health and Medicare Protection Act of 2007; S.965,U.S. Troop Readiness, Veterans' Care, Katrina Recovery, and Iraq Accountability Appropriations Act, 2007. H.R.4, Medicare Prescription Drug Price Negotiation Act of 2007; H.R.3162, Children's Health and Medicare Protection Act of 2007; S.3, Medicare Prescription Drug Price Negotiation Act of 2007; S.250, Medicare Enhancements for Needed Drugs Act of 2007;

17. House(s) of Congress and Federal agencies contacted:
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ATKINS, LARRY
Covered Official Position (if applicable): N/A
Name: EHRLICH, PAUL
Covered Official Position (if applicable): N/A
Name: LIVELY, ROBERT W.
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Feb 14, 2008

Printed Name and Title: MARRA R BUSSEY, ASSOCIATE, CORPORATE GOVERNMENT AF -

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Feb 14, 2008

Printed Name and Title: -